

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 May 2026

### Comparing the effect of Dexmedetomidine and Remifentanil on post operative pain control after spine surgery

#### Protocol summary

##### Study aim

Dexmedetomidine versus remifentanil in post operative pain control after spine surgery.

##### Design

Clinical trial with double- blinded postoperative care and outcome assessment. Randomisation will be carried out using random digits table.

##### Settings and conduct

This double-blinded clinical trial will be done in Ahwas Golestan hospital. In this study patients and anesthesiologist will be kept blind.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: age 18-65 ;elective spine surgery;ASA class 1and 2. Exclusion criteria: previous spine surgery; opium addiction;alcohol addiction; neurological, neuromuscular, psychological, pulmonary and cardiovascular diseases; prolonged usage of analgesic (cox-2 inhibitors); intra operative unpredictable events such as massive bleeding.

##### Intervention groups

Intervention group 1:Dexmedetomidine group(Dexmedetomidine single-dose before general anesthesia and dexmedetomidine infusion durig operation),Intervention group 2:Remifentanil group(Remifentanil single\_dose before general anesthesia and remifentanil infusion during operation)

##### Main outcome variables

Pain; systolic blood pressure; diastolic blood pressure; heart rate; arterial oxygen saturation.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20191023045206N1**

Registration date: **2020-05-06, 1399/02/17**

Registration timing: **retrospective**

Last update: **2020-05-06, 1399/02/17**

Update count: **0**

##### Registration date

2020-05-06, 1399/02/17

##### Registrant information

###### Name

Mohammad Zafari

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 61 3333 3050

###### Email address

mohammad.zafari2@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-12-01, 1398/09/10

##### Expected recruitment end date

2020-03-19, 1398/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparing the effect of Dexmedetomidine and Remifentanil on post operative pain control after spine surgery

##### Public title

Dexmedetomidine versus remifentanil in post operative pain control after spine surgery

##### Purpose

Diagnostic

##### Inclusion/Exclusion criteria

**Inclusion criteria:**

Elective surgery of spine age of 18-65 years ASA class 1,2

**Exclusion criteria:**

Previous spine surgery Opium addiction Alcohol addiction Neurological disease Neuromuscular disease Psychological disease Pulmonary disease Cardiovascular disease Analgesic consumer(cox-2 inhibitors) Operative unpredictable events (massive bleeding)

**Age**

From **18 years** old to **65 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

In this study spinal surgery patients will be divided to two groups receiving dexmedetomidine and remifentanyl in random using random digits table.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The anesthesiologist who has responsible for the patients management of anesthesia will administer the medicine (s) via coded syringes had been prepared previously and will not aware of the injected drug (dexmedetomidin or remifentanyl), and anesthesia nurse who is responsible for collection of patients information and study variables is unaware of the administered drug will record the check- list during surgery and in the recovery. Also the patient is unaware of the injected medicine.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Ahwaz University of Medical Sciences

**Street address**

Golestan hospital; Golestan avenue

**City**

Ahwaz

**Province**

Khouzestan

**Postal code**

6136763316

**Approval date**

2019-11-16, 1398/08/25

**Ethics committee reference number**

IR.AJUMS.REC.1398.593

**Health conditions studied****1****Description of health condition studied**

Post operative pain

**ICD-10 code**

R52.9

**ICD-10 code description**

Pain, unspecified

**Primary outcomes****1****Description**

Pain

**Timepoint**

30, 60 and 120 minutes and 24 hours after surgery

**Method of measurement**

Visual Analogue Scale

**Secondary outcomes****1****Description**

Systolic blood pressure variance

**Timepoint**

30, 60 and 120 minutes and 24 hours after surgery

**Method of measurement**

blood pressure monitor

**2****Description**

Diastolic blood pressure variance

**Timepoint**

30, 60 and 120 minutes and 24 hours after surgery

**Method of measurement**

blood pressure monitoring

**3****Description**

Heart rate variance

**Timepoint**

30, 60 and 120 minutes and 24 hours after surgery

**Method of measurement**

heart rate monitoring

## 4

### Description

O2 saturation variance

### Timepoint

30, 60 and 120 minutes and 24 hours after surgery

### Method of measurement

Pulseoxymetry

## Intervention groups

### 1

#### Description

Intervention group1:serum ringer lactate 5 ml/kg,midazolam 0.02 mg/kg,fentanyl 2mcg/kg,propofol1.5 mg/kg,atracurium 0.5 mg/kg,morphine sulfate 0.1 mg/kg for induction and dexmedetomidine0.1mcg/kg in 10 minutes(Abureyhan \_Iran co.) and for maintenance propofol 100 to 150 mcg/kg besides dexmedetomidine0.1mcg/kg/h will receive.

#### Category

Diagnosis

### 2

#### Description

Intervention group2:serum ringer lactate 5 ml/kg,midazolam 0.02 mg/kg,fentanyl 2mcg/kg,propofol1.5 mg/kg,atracurium 0.5 mg/kg,morphine sulfate 0.1 mg/kg for induction and remifentanyl bolus dose(Abureyhan \_Iran co.) 1 mcg/kg and for maintenance propofol 100 to 150 mcg/kg besides 1 mcg/kg/min remifentanyl will receive.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Ahwaz Golestan hospital

##### Full name of responsible person

Mohammad Zafari

##### Street address

Golestan avenue

##### City

Ahwaz

##### Province

Khuzestan

##### Postal code

6136763316

##### Phone

+98 61 3374 3348

##### Email

mohammad.zafari2@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Ahwaz University of Medical Sciences

##### Full name of responsible person

Farahzad Jannatmakan

##### Street address

Golestan avenue

##### City

Ahwaz

##### Province

Khuzestan

##### Postal code

6136763376

##### Phone

+98 61 3376 8483

##### Email

mohammad.zafari2@yahoo.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Ahwaz University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Ahwaz University of Medical Sciences

##### Full name of responsible person

Farahzad Janatmakan

##### Position

Professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Anesthesiology

##### Street address

Golestan avenue

##### City

Ahwaz

##### Province

Khuzestan

##### Postal code

6136766337

##### Phone

+98 61 3374 8388

**Email**

janatmakan-f@ajums.ac.ir

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Nozar Nassajian

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Golestan avenue

**City**

Ahwaz

**Province**

Khouzestan

**Postal code**

6136768831

**Phone**

+98 61 3376 6841

**Email**

nasajian-n@ajums.ac.ir

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Sara Jarir Ahmadi

**Position**

Consultant

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Golestan avenue

**City**

Ahwaz

**Province**

Khouzestan

**Postal code**

61377641112

**Phone**

0098 61 3374551441

**Email**

jarirahmadi-s@ajums.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

data after the end of study will be available.

**When the data will become available and for how long**

from 2021

**To whom data/document is available**

physicians

**Under which criteria data/document could be used**

using for future studies.

**From where data/document is obtainable**

send E-Mail to Mohammad.zafari2@yahoo.com

**What processes are involved for a request to access data/document**

filling the study request form

**Comments**